Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide

• Asıl Yazarlar: Daniel N. Marco (Yazar), María Queralt Salas (Yazar), Gonzalo Gutiérrez-García (Yazar), Inés Monge (Yazar), Gisela Riu (Yazar), Esther Carcelero (Yazar), Joan Ramón Roma (Yazar), Noemí Llobet (Yazar), Jordi Arcarons (Yazar), María Suárez-Lledó (Yazar), Nuria Martínez (Yazar), Alexandra Pedraza (Yazar), Ariadna Domenech (Yazar), Laura Rosiñol (Yazar), Francesc Fernández-Avilés (Yazar), Álvaro Urbano-Ispízua (Yazar), Montserrat Rovira (Yazar), Mercè Brunet (Yazar), Carmen Martínez (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: MDPI AG, 2022-12-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Tacrolimus (Tac) is a pivotal immunosuppressant agent used to prevent graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloHSCT). Tac is characterized by a narrow therapeutic window and a high inter-patient and intra-patient pharmacokinetic variability (IPV). Although hig...